vs
Side-by-side financial comparison of TScan Therapeutics, Inc. (TCRX) and zSpace, Inc. (ZSPC). Click either name above to swap in a different company.
zSpace, Inc. is the larger business by last-quarter revenue ($4.8M vs $2.6M, roughly 1.9× TScan Therapeutics, Inc.). zSpace, Inc. runs the higher net margin — -150.3% vs -895.1%, a 744.8% gap on every dollar of revenue.
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel T cell receptor (TCR) immunotherapies for hard-to-treat cancers. Its proprietary platform identifies high-affinity naturally occurring TCRs targeting tumor antigens, with pipeline candidates spanning hematological malignancies and solid tumors, operating in the global oncology therapeutics market.
zSpace, Inc. is an American technology firm based in San Jose, California that delivers virtual and augmented reality experiences in STEM, CTE, and career readiness programs from a computer. zSpace mostly provides AR/VR technology to the education market, allowing teachers and learners to interact with simulated objects in virtual environments.
TCRX vs ZSPC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.6M | $4.8M |
| Net Profit | $-23.0M | $-7.3M |
| Gross Margin | — | 49.1% |
| Operating Margin | -929.4% | -116.2% |
| Net Margin | -895.1% | -150.3% |
| Revenue YoY | 286.0% | — |
| Net Profit YoY | 35.8% | — |
| EPS (diluted) | $-0.18 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.6M | $4.8M | ||
| Q3 25 | $2.5M | $8.8M | ||
| Q2 25 | $3.1M | $7.5M | ||
| Q1 25 | $2.2M | $6.8M | ||
| Q3 24 | $1.0M | — | ||
| Q4 23 | $7.2M | — | ||
| Q3 23 | $3.9M | — | ||
| Q2 23 | $3.1M | — |
| Q4 25 | $-23.0M | $-7.3M | ||
| Q3 25 | $-35.7M | $-6.2M | ||
| Q2 25 | $-37.0M | $-6.1M | ||
| Q1 25 | $-34.1M | $-5.8M | ||
| Q3 24 | $-29.9M | — | ||
| Q4 23 | $-19.6M | — | ||
| Q3 23 | $-23.0M | — | ||
| Q2 23 | $-24.0M | — |
| Q4 25 | — | 49.1% | ||
| Q3 25 | — | 51.2% | ||
| Q2 25 | — | 42.6% | ||
| Q1 25 | — | 47.4% | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | -929.4% | -116.2% | ||
| Q3 25 | -1475.6% | -54.5% | ||
| Q2 25 | -1256.6% | -84.9% | ||
| Q1 25 | -1669.7% | -79.7% | ||
| Q3 24 | -3109.8% | — | ||
| Q4 23 | -296.2% | — | ||
| Q3 23 | -636.7% | — | ||
| Q2 23 | -781.8% | — |
| Q4 25 | -895.1% | -150.3% | ||
| Q3 25 | -1422.1% | -70.2% | ||
| Q2 25 | -1201.3% | -81.8% | ||
| Q1 25 | -1571.9% | -86.3% | ||
| Q3 24 | -2849.1% | — | ||
| Q4 23 | -272.0% | — | ||
| Q3 23 | -591.6% | — | ||
| Q2 23 | -763.8% | — |
| Q4 25 | $-0.18 | $-0.22 | ||
| Q3 25 | $-0.28 | $-0.26 | ||
| Q2 25 | $-0.28 | $-0.27 | ||
| Q1 25 | $-0.26 | $-0.26 | ||
| Q3 24 | $-0.25 | — | ||
| Q4 23 | $0.32 | — | ||
| Q3 23 | $-0.24 | — | ||
| Q2 23 | $-0.51 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $152.4M | — |
| Total DebtLower is stronger | $32.5M | $17.7M |
| Stockholders' EquityBook value | $123.1M | $-22.5M |
| Total Assets | $228.8M | $7.6M |
| Debt / EquityLower = less leverage | 0.26× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $152.4M | — | ||
| Q3 25 | $184.5M | — | ||
| Q2 25 | $218.0M | — | ||
| Q1 25 | $251.7M | — | ||
| Q3 24 | $271.1M | — | ||
| Q4 23 | $192.0M | — | ||
| Q3 23 | $215.4M | — | ||
| Q2 23 | $208.8M | — |
| Q4 25 | $32.5M | $17.7M | ||
| Q3 25 | $32.4M | $18.7M | ||
| Q2 25 | $32.3M | $18.1M | ||
| Q1 25 | $32.2M | — | ||
| Q3 24 | $30.6M | — | ||
| Q4 23 | $30.0M | — | ||
| Q3 23 | $29.9M | — | ||
| Q2 23 | $29.7M | — |
| Q4 25 | $123.1M | $-22.5M | ||
| Q3 25 | $144.0M | $-19.7M | ||
| Q2 25 | $176.7M | $-22.3M | ||
| Q1 25 | $210.2M | $-19.6M | ||
| Q3 24 | $229.1M | — | ||
| Q4 23 | $150.9M | — | ||
| Q3 23 | $169.0M | — | ||
| Q2 23 | $190.6M | — |
| Q4 25 | $228.8M | $7.6M | ||
| Q3 25 | $262.2M | $13.5M | ||
| Q2 25 | $298.6M | $12.1M | ||
| Q1 25 | $332.7M | $9.8M | ||
| Q3 24 | $348.0M | — | ||
| Q4 23 | $272.1M | — | ||
| Q3 23 | $291.4M | — | ||
| Q2 23 | $316.9M | — |
| Q4 25 | 0.26× | — | ||
| Q3 25 | 0.23× | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.15× | — | ||
| Q3 24 | 0.13× | — | ||
| Q4 23 | 0.20× | — | ||
| Q3 23 | 0.18× | — | ||
| Q2 23 | 0.16× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-32.0M | $-3.9M |
| Free Cash FlowOCF − Capex | $-32.2M | — |
| FCF MarginFCF / Revenue | -1253.3% | — |
| Capex IntensityCapex / Revenue | 6.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-139.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-32.0M | $-3.9M | ||
| Q3 25 | $-32.5M | $-2.5M | ||
| Q2 25 | $-33.3M | $-6.9M | ||
| Q1 25 | $-37.6M | $-4.6M | ||
| Q3 24 | $-27.9M | — | ||
| Q4 23 | $-23.8M | — | ||
| Q3 23 | $8.0M | — | ||
| Q2 23 | $-22.0M | — |
| Q4 25 | $-32.2M | — | ||
| Q3 25 | $-33.9M | — | ||
| Q2 25 | $-34.5M | — | ||
| Q1 25 | $-39.1M | — | ||
| Q3 24 | $-29.3M | — | ||
| Q4 23 | $-24.2M | — | ||
| Q3 23 | $6.6M | — | ||
| Q2 23 | $-22.4M | — |
| Q4 25 | -1253.3% | — | ||
| Q3 25 | -1349.6% | — | ||
| Q2 25 | -1123.1% | — | ||
| Q1 25 | -1801.8% | — | ||
| Q3 24 | -2792.0% | — | ||
| Q4 23 | -336.1% | — | ||
| Q3 23 | 169.7% | — | ||
| Q2 23 | -712.9% | — |
| Q4 25 | 6.7% | — | ||
| Q3 25 | 56.8% | — | ||
| Q2 25 | 41.6% | — | ||
| Q1 25 | 70.6% | — | ||
| Q3 24 | 130.6% | — | ||
| Q4 23 | 6.5% | — | ||
| Q3 23 | 36.5% | — | ||
| Q2 23 | 13.3% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TCRX
Segment breakdown not available.
ZSPC
| Transferred At Point In Time | $4.6M | 94% |
| Other | $287.0K | 6% |
